Table 4

ORs for SLE patients with different Hsp70-4 genotypes and haplotypes (Hsp70-4 and -5) based on the presence of anti-Ro and anti-La autoantibodies

Population: Hsp70-4 genotypesAutoantibodies againstp ValueOR95% CI
ErlangenRo
 C/C versus T/T0.022.741.15 to 6.52
 C/C versus C/T0.022.151.12 to 4.13
La
 C/C versus T/T0.023.011.18 to 7.70
 C/C versus C/TNS1.360.63 to 2.97
OMRFRo
 C/C versus T/TNS1.270.68 to 2.37
 C/C versus C/T0.031.671.04 to 2.68
La
 C/C versus T/T0.022.731.12 to 6.65
 C/C versus C/T0.0013.241.53 to 6.88
Population: haplotypes (Hsp70-4 and Hsp-5)Autoantibodies againstp ValueOR95% CI
ErlangenRo
 C–G/C–G versus T–G/T–G0.0045.141.57 to 16.84
 C–G/C–G versus C–G/T–G0.0013.211.58 to 6.53
La
 C–G/C–G versus T–G/T–G0.014.171.29 to 13.55
 C–G/C–G versus C–G/T–GNS1.910.85 to 4.29
OMRFRo
 C–G/C–G versus T–G/T–GNS1.650.78 to 3.50
 C–G/C–G versus C–G/T–GNS1.650.97 to 2.69
La
 C–G/C–G versus T–G/T–G0.052.720.97 to 7.66
 C–G/C–G versus C–G/T–G0.0072.811.30 to 6.05
  • ORs were calculated using χ2 test.

  • OMRF, Oklahoma Medical Research Foundation; SLE, systemic lupus erythematosus.